Levels of anticardiolipin and anti-β₂-glycoprotein I antibodies in healthy newborn cord sera

• References

• 1 Myakis S, Lockhin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
• 2 Ruffati A, Tonello M, Del Ross T. et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96: 337-341.
• 3 Boffa MC, Lachassine E. Infant perinatal thrombosis and antiphospholipid antibodies. A review. Lupus 2007; 16: 634-641.
• 4 Motta M, Chirico G. Rebaioli et al. Anticardiolipin and anti-β2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Pernatol 2006; 23: 247-251.
• 5 Cohen SB, Goldenberg M, Rabinovici J. et al. Anticardiolipin antibodies in fetal blood and amniotic fluid derived from patients with the antiphospholipid syndrome. Hum Reprod 2000; 15: 1170-1172.
• 6 Soares Rolim AM, Castro M, Santiago MB. Neonatal antiphospholipid syndrome. Lupus 2006; 15: 301-303.
• 7 Carbillon L, Letamendia-Richard E, Lachassine E. et al. Neonatal thrombosis associated with maternal antiphospholipid syndrome. J Pediat Hematol Oncol 2005; 27: 56.
• 8 Cabiedes J, Trjo-Hernadez J, Loredo-Abdala A. et al. Anticardiolipin, anticardiolipin plus bovine or human β2glycoprotein I and anti human β2glycoprotein I antibodies in a healthy infant population. Arch Med Res 2002; 33: 175-179.
• 9 Avcin T, Ambrozic A, Kuhar M. et al. Anticardiolipin and anti-β2 glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology 2001; 40: 565-573.
• 10 Rapizzi E, Ruffati A, Tonello M. et al. Correction for age of anticardiolipin antibodies cut-off points. J Clin Lab Anal 2000; 14: 87-90.
• 11 Gattorno M, Buoncompagni A, Molinari AC. et al. Antiphosholipid antibodies in pediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high titer anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Br J Rheumatol 1995; 34: 873-881.
• 12 Siamopoulou-Mavridou A, Mavridis AK, Terzoglou C. et al. Autoantibodies in Greek juvenile chronic arthritis patients. Clin Exp Rheumatol 1991; 9: 647-652.
• 13 Serra CR, Rodrigues SH, Silva NP. et al. Clinical significance of anticardiolipin antibodies in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999; 17: 375-380.
• 14 Tincani A, Allegri F, Ballestrieri G. et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-558.
• 15 Jones JV, Eastwood BJ. Jones et al. Antiphospholipid antibodies in a healthy population: methods for estimating the distribution. J Rheumatol 1995; 22: 55-61.
• 16 Hayward AR. The human fetus and newborn: development of the immune response. Birth defects Orig Artic Sem 1983; 19: 289-294.
• 17 Angelini L, Ravelli A, Caporali R. et al. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics 1994; 94: 500-503.
• 18 Reber G, Shousboe I, Tincani A. et al. Inter-laboratory variability of antiβ2glycoprotein I measurements. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
• 19 Boffa MC, Aurousseau MH, Lachassine E. et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus 2004; 13: 1-5.